Recent Event Highlights: ChemGenex Completes pre-NDA Meeting with US FDA and Clarifies Timing for ... - PharmaLive.com (press release), Accident led to cancer treatment for 'Philadelphia chromosome' - Philadelphia Inquirer, Dr. Ian Flinn, Director of Hematologic Malignancies Research Program, CML Patients: Survivors Changing The Language of Cancer - EmpowHer, EU committee recommends approval of Novartis drug Tasigna to treat patients ... - pharmabiz.com, Don't Stop Imatinib in GIST or CML: Continuous Treatment Needed - Medscape, and 89 more...
Created by dipity on Nov 10, 2009
Last updated: 11/03/10 at 11:34 PM
Cml Leukemia has no followers yet. Be the first one to follow.
ChemGenex Completes pre-NDA Meeting with US FDA and Clarifies Timing for ...PharmaLive.com (press release)... mepesuccinate) for the treatment of patients with Chronic Myeloid Leukemia (CML) who have failed two or more tyrosine kinase inhibitors (TKIs). ...and more »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHcI5LvxNI1gdYZ7VV_bd8EWrwPTA&url=http://www.pharmalive.com/News/index.cfm?articleid%3D733982%26categoryid%3D51
WHYY (blog)Accident led to cancer treatment for 'Philadelphia chromosome'Philadelphia InquirerNow he's intimately familiar with this bit of errant genetic material that triggers his particular form of the disease - chronic myeloid leukemia (CML). ...Today is Philadelphia Chromosome DayWHYY (blog)all 3 news articles »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHqTCnG_eKKSnQANhbjI2lXasQNdQ&url=http://www.philly.com/inquirer/front_page/20100929_Accident_led_to_cancer_treatment_for__Philadelphia_chromosome_.html
Sarah Cannon, Research Institute & Jason Green, Chronic Myeloid Leukemia Patient Leukemia & Lymphoma Awareness Month is in September and Dr. Ian Flinn, will share information about how the patient benefits from clinical trials as well as the overall importance of them in terms of healthcare for the public. Patient Jason Green who was involved with the on such trial, will join Dr Flinn to talks about his courage and determination that led him to get involved with the clinical trials. September is Leukemia & Lymphoma Awareness Month Leading Researcher and Patient Team Up During to Discuss the Importance of Clinical Trials for Finding New Cancer Treatments As the cost of healthcare continues to skyrocket out of control, more and more people are learning how to become pro-active when it comes to their health. We've all heard about the standard things we should be doing like eating more fruits/veggies and less processed foods, exercising for at least 30 minutes a day, and making sure we don't smoke or drink too much alcohol. But what about more alternative ideas--especially if you already have an illness that requires costly hospital and doctor visits--not to mention expensive drugs. One cutting edge option is finding out how to get involve during the "clinical trial" stage of an experimental drug. www.SarahCannonResearch.com This is something to try when you have a more serious disease like cancer. Leukemia & Lymphoma Awareness Month is in September, and Dr. Ian Flinn ...
CML Patients: Survivors Changing The Language of CancerEmpowHerThe best example currently of a treatable cancer is CML, also known as chronic myelogenous leukemia, chronic myeloid leukemia and chronic myelocytic ...
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFHlTPIAdexKm533cpfMm3mQnA8Kw&url=http://www.empowher.com/cancer/content/cml-patients-survivors-changing-language-cancer
EU committee recommends approval of Novartis drug Tasigna to treat patients ...pharmabiz.comChronic myeloid leukemia is one of the four most common types of leukaemia, responsible for about 15% of all leukaemia cases worldwide. ...and more »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHzbfnhxzUCSkPI4ElOSghdGFJsBQ&url=http://www.pharmabiz.com/article/detnews.asp?articleid%3D57530%26sectionid%3D
Don't Stop Imatinib in GIST or CML: Continuous Treatment NeededMedscapeThis conclusion, published online September 22 in the Lancet Oncology, echoes previous findings from studies of chronic myeloid leukemia (CML). ...and more »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNGbLHmq2l7WehEIgfWQr_PzUFxN_Q&url=http://www.medscape.com/viewarticle/729359
Novartis applauds declaration of CML Awareness Day in CanadaNews-Medical.netNovartis congratulates the CML Society for their creation and recognition of this important day. CML is one of four types of leukemia. ...
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNETwN7AuphTmfOANzuf8tIQW-kvBg&url=http://www.news-medical.net/news/20100923/Novartis-applauds-declaration-of-CML-Awareness-Day-in-Canada.aspx
TSX & TSX Venture Stock QuotesCanada NewsWire (press release)Established in 2006, the CML (Chronic Myelogenous Leukemia) Society provides support, education and information on CML, current and emerging treatments and ...and more »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNF8h6gYsLTkHians9tlmJDB4y-nTw&url=http://www.newswire.ca/en/releases/archive/September2010/22/c3891.html
One blood cancer survivor speaks to a group of "Team in Training" athletes at the pre-race pasta party on September 18th, 2010 in Philadelphia. This remarkable group of people raised more than $200000 (and counting) while training for 3 months to help in the fight against blood cancers. Google "Team in Training" or "Leukemia and Lymphoma Society" for more info. Tell them a Philly survivor sent you! Or if you wish to make a donation visit: pages.lightthenight.org
myfoxny.comLight The Night For Cancer Researchmyfoxny.comParticipants, including legendary basketball legend and CML survivor Kareem Abdul-Jabbar, will walk to raise more than $2.1 million for vital life-saving ...and more »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNH5dB_36z-Vj46N5SV39it4dRei1A&url=http://www.myfoxny.com/dpp/about_us/public_affairs/light-the-night-for-cancer-research
Chronic Myelogenous Leukemia Research ProgressEmpowHer (blog)All forms of leukemia have similar symptoms, but the treatments differ. Chronic myelogenous leukemia (CML) is caused by a defect in one ...
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNHreJBDqlcJicuacOGYg8Q1uPQP8g&url=http://www.empowher.com/chronic-myelocytic-leukemia/content/chronic-myelogenous-leukemia-research-progress
ARIAD Announces Initiation of Ponatinib (AP24534) Pivotal Trial in Drug ...MarketWatch (press release)... in patients with resistant or intolerant chronic myeloid leukemia (CML) and Philadelphia positive acute lymphoblastic leukemia (Ph+ ALL). ...Ariad, Cyclacel To Start Key Drug TrialsTheStreet.comall 25 news articles »
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNFPI2KWbqOhRNQZTYo96sMsPavJvA&url=http://www.marketwatch.com/story/ariad-announces-initiation-of-ponatinib-ap24534-pivotal-trial-in-drug-resistant-or-intolerant-chronic-myeloid-leukemia-2010-09-13?reflink%3DMW_news_stmp
Diagnosed six years earlier with chronic myelogenous leukemia, a cancer of the blood, Doug, now age 75, was told there was nothing the doctors could do for him. But he found new hope in an experimental treatment that signals the cancerous cells to stop duplicating -- effectively managing, though not curing, the disease. To learn more about CML and other blood disorders, visit ASH's patient information site www.bloodthevitalconnection.org. This clip was excerpted from the documentary film "Blood Detectives." To learn more about the film, visit http
Chronic myeloid leukemia, or CML, was once considered a death sentence but new treatment options have turned CML into a chronic, yet manageable disease for most patients. Distributed by Tubemogul.
Tasigna® only treatment to surpass Gleevec in slowing disease progression for newly diagnosed CML patients data to be presented at 46th Annual ASCO meeting www.novartis.com www.asco.org Longer-term, 18-month, data from a pivotal study being presented at the 46th Annual Meeting of the American Society for Clinical Oncology (ASCO), shows that Tasigna® (nilotinib) 200 mg capsules continues to demonstrate superiority to the standard of care, Gleevec, as a first-line treatment in patients with Philadelphia chromosome-positive Chronic Myeloid Leukemia (Ph+ CML). CML is a disease in which the body produces cancerous white blood cells and is responsible for 10 to 15 percent of all adult cases of leukemia. In 2009 alone, there were more than 5000 newly diagnosed cases of CML in the United States. In 2001, Gleevec® (imatinib mesylate) tablets* revolutionized the treatment of Ph+ CML, becoming the gold standard of care by demonstrating the highest overall survival rate observed for people with this type of cancer. The longest-term comparative study of a second-generation tyrosine kinase inhibitor to date — Tasigna induced more than twice the major molecular response (MMR) rate compared with Gleevec and resulted in significantly lower rates of progression to advanced disease. Findings based on preliminary data, which will need to be confirmed by longer-term follow-up, also indicated that the drug positively impacted patient survival outcomes. Analysis of event-free survival ...
This videos is the second part to my first video about me finding out I have cancer.
This video I made is to help explain my reaction to getting told I have cancer.
this video shows the end result and skips the process of making it. this is for people who just want to see how it turned out. if you want to see how the horse was made click here: www.youtube.com to see the wings with the quotes click here: www.youtube.com horse is for awareness of different kinds of cancers with quotes from survivors and those diagnosed (see other video with the wing footage for quotes) proceeds from this cancer awareness horse go to the City of Hope and the Hope Lodge (for discovery of cures and support for people who are diagnosed) SITES: www.amysarmy.org/ (help amy and others like her) www.cityofhope.org (on the verge of curing cml leukemia, stage 4 breast cancer, etc) www.leukemia.org (help find cures for people diagnosed and their families) www.dkmsamericas.org (see if your marrow can be a match for someone diagnosed) www.cancer.org (american cancer society)
quotes on one of the horse's wings. to see the whole horse check out my other video: www.youtube.com I ALSO URGE YOU TO SEE THE VIDEO OF THE WHOLE HORSE B/C TRUST ME IT IS NOT BLACK. IT GLOWS WITH LAYERS OF SOFTLY BLENDED COLORS. but this video focuses just on the quotes. song is by Within Temptation, Stand My Ground. i have their cd and no copyright infringement is intended. SITES: www.amysarmy.org/ (help amy and others like her) www.cityofhope.org (on the verge of curing cml leukemia, stage 4 breast cancer, etc) www.leukemia.org (help find cures for people diagnosed and their families) www.dkmsamericas.org (see if your marrow can be a match for someone diagnosed) www.cancer.org (american cancer society)
TO SKIP THE STAGES AND SEE HOW IT TURNED OUT SKIP TO 7:46 (but it is fun to see the stages) showing the many stages of my horse for Horse Mania. named Hope designed to be astral on one side and Pegasus's constellation on the other. its theme is cancer awareness and has stories and quotes form people stricken with cancer. healthy people think hardly of these cancers until someone they know has one so hopefully this will spread the word and encourage people to educate themselves and help find a cure. whether its donating money to the following groups at the end of this video, donating blood or marrow, every little bit helps. ALSO CHECK OUT THE VIDEO OF THE QUOTE'S ON THE HORSE'S WINGS AT: www.youtube.com SITES: www.amysarmy.org/ (help amy and others like her) www.cityofhope.org (on the verge of curing cml leukemia, stage 4 breast cancer, etc) www.leukemia.org (help find cures for people diagnosed and their families) www.dkmsamericas.org (see if your marrow can be a match for someone diagnosed) www.cancer.org (american cancer society)
A new drug with a similar but more potent mechanism of action as imatinib, commonly known as Gleevec, appears to be more effective for the treatment of chronic myeloid leukemia, according to research published in the New England Journal of Medicine. Here is some information about chronic myeloid leukemia: • Also known as CML, it is a slow progressing cancer found in the blood and bone marrow • It results in the overgrowth of immature, malfunctioning white blood cells • A major cause of CML is believed to be a genetic mutation that results in the development of an abnormal chromosome called BCR-ABL Researchers from the University of Turin treated nearly 850 patients suffering from CML with either a low dose or a high dose of a new drug known as nilotinib or with Gleevec. The patients were followed up for a year. At the end of the follow-up period, more than twice as many of the patients on nilotinib as on Gleevec experienced a major molecular response to their treatment, meaning the products of BCR-ABL were nearly undetectable in the blood. Similarly, more patients taking nilotinib than Gleevec had a complete cytogenic response, meaning cells containing the BCR-ABL mutation could not be detected in the blood or bone marrow. Those taking nilotinib were also less likely to experience a progression of their disease. We spoke with Dr. Giuseppe Saglio, one of the investigators of this study, who offered some further insight. Today's research suggests that a new, more powerful ...
Welcome to OncoFacts for February, 2010. For this issue of OncoFacts, we are going to focus on some of the most interesting data presented at the American Society of Hematology (ASH) Annual Meeting. We will discuss some of the data presented at the ASH Annual Meeting in the areas of multiple myeloma, myeloproliferative neoplasms, and myelodysplastic syndrome (MDS). Next month, we will look at data from the ASH Annual Meeting regarding chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), and lymphomas.
MD Anderson researchers play crucial role in two New England Journal of Medicine studies showing newer drugs for chronic myeloid leukemia work faster and better than imatinib (Gleevec®).
Chronic Myeloid Leukemia What Is CML Symptoms and Treatment of Video a7lm cc
Dr. Susan Branford discusses the future direction of molecular monitoring in CML.
Mnemonic Learning Aid for CML (Chronic Myelogenous Leukemia) in Pictorial format. Brought to you by pictorialmnemonics.com
Imatinib (Gleevec) has become a paradigm for targeted cancer therapies. The first part of this lecture will describe the clinical features and the molecular pathogenesis of the disease for which imatinib was developed, chronic myeloid leukemia (CML). This overview will trace the history of the identification of the target of imatinib, BCR-ABL. The preclinical development of the BCR-ABL kinase inhibitor, imatinib and highly successful clinical trials of this agent for patients with CML will be reviewed along with the most up-to-date follow-up on these studies. See more at www.ibioseminars.org
Imatinib (Gleevec) has become a paradigm for targeted cancer therapies. Although the majority of patients with chronic myeloid leukemia (CML) respond well to imatinib, a minority of patients have relapsed. This part of the lecture will cover what has been learned about mechanisms of relapse and how this information has been translated into new therapies for patients with imatinib resistance. Although imatinib is a relatively specific inhibitor of the ABL kinase, a couple of other kinases, KIT and the platelet derived growth factor receptor are also inhibited by imatinib. This use of this information to treat successfully treat other malignant diseases driven by these kinases will be reviewed. See more at www.ibioseminars.org
Imatinib has become the paradigm of targeted drug development. The lessons learned from the clinical trials of imatinib treatment of chronic myeloid leukemia will be reviewed in this section. This will include examples of where imatinib has or has not worked, analysis of target expression versus activation and a discussion of how the success of imatinib can be translated to other malignancies. The section concludes with what this means for research to control or cure cancer in the coming decades. See more at www.ibioseminars.org
Fundraising video that i created for my third time participating in the event. For the fourth year in a row, I have participated in the Scott Firefighter Stair Climb in Seattle, WA. A grueling climb up 1311 steps and 69 floors in full firefighter combat gear, but nothing compares to the battle a Leukemia patient and family must go through. The first year I set what I thought was a goal that was not in reach and surpassed it. Last year I again thought my goal was unreachable, yet through your support I went beyond once again. This year I have set my goal slightly higher to make myself go the extra mile in fundraising. Knowing that every dollar raised goes to help with research, patient services, and education of Leukemia patients makes my climb worthwhile. On a personal level the event and the cause is motivating for me. My mother Peggy was diagnosed with Chronic Mylogenous Leukemia that nearly took her life beginning in 1986. Her long battle with the disease, its many side effects, and its treatments slowly worked to weaken her body nearly taking her life several times. Her long battle with CML ended with a miracle when she received a bone marrow transplant in 1990. The unmatched, unrelated bone marrow transplant was the first of its kind at The Ohio State University and was before the James Cancer Institute came to fruition. Without fundraisers such as this stairclimb, money for research, patient support, education, and assistance, her life may not have been saved. Help ...
Our one return visit to a very difficult cache in Palo Duro Canyon, one year and 5 days later. While at the summit of the ascent, but half a mile north of the "Lost Canyon Cache" we placed our own "summit view" Geocache box. It's a hell of a hike to get here, but if you ever had the chance, TAKE IT! It's awsome, an area of the park untouched by most visitors, be one of the few to see it. for more information on our hobbies visit WWW.GEOCACHING.COM
OHSU's Brian Druker Receives 2010 Portland First Citizen AwardMedia Newswire (press release)... scheduled for April 21, 2010, at the Governor Hotel, from 11:30 am to 1:30 pm Druker specializes in the treatment of chronic myeloid leukemia ( CML ). ...
http://news.google.com/news/url?fd=R&sa=T&url=http%3A%2F%2Fmedia-newswire.com%2Frelease_1111847.html&usg=AFQjCNHfjNQ3DRQwOiR7SBQuqyYDabG-WQ
MEDCAC Review of PGx Cancer Tests Finds Some Clinical Utility, More ...GenomeWeb Daily NewsPharmacogenomic tests to guide treatment with Herceptin for breast cancer, Gleevec in chronic myelogenous leukemia, and Vectibix and Erbitux ...and more »
http://news.google.com/news/url?fd=R&sa=T&url=http%3A%2F%2Fwww.genomeweb.com%2Fdxpgx%2Fmedcac-review-pgx-cancer-tests-finds-some-clinical-utility-more-evidentiary-gaps&usg=AFQjCNHRgYWjIgtALNWv8_papSOPaQiHeQ
The Money TimesStudy: Bone marrow and stem cell transplants result in similar survival ratPrivate MDFor patients with chronic myeloid leukemia (CML), there were no significant differences in terms of long-term survival. "This update comparing two important ...Stem Cell Transplant Source Does Not Affect Long-Term Leukemia OutcomesMedPage TodayLeukemia: Bone Marrow vs. Blood Stem CellsIvanhoeNo difference in survival between leukaemia patients 10 years after undergoing ...PhysOrg.comThe Money Timesall 50 news articles »
http://news.google.com/news/url?fd=R&sa=T&url=http%3A%2F%2Fwww.privatemdlabs.com%2Fnews%2FLeukemia_and_WBC_disorders%2FStudy%3A-Bone-marrow-and-stem-cell-transplants-result-in-similar-survival-rat%2419593752.php&usg=AFQjCNFBJ8JL714eHB6dbn7NaAL9LWql1w
A video presentation of BSN-3C of Ateneo de Davao University... 2009-2010 CHRONIC MYELOID LEUKEMIA
a video presentation of bsn-3c of ateneo de davao university... CHRONIC MYELOID LEUKEMIA
Personalized Cancer Care Off to Slow StartGoozNew (blog)The study looked at whether the presence of specific mutations in people who had breast and colon cancer and chronic myeloid leukemia determined if patients ...
http://news.google.com/news/url?fd=R&sa=T&url=http%3A%2F%2Fwww.gooznews.com%2Fnode%2F3250&usg=AFQjCNFi4EKDQUnNylHVrqgnyvqKDha6-Q
Vaccine may “mop up” Leukemia cells Gleevec leaves behindEmpowHer (blog)Preliminary studies show a vaccine made with leukemia cells may be able to prevent a relapse in some chronic myeloid leukemia (CML) patients taking the drug ...
http://news.google.com/news/url?fd=R&sa=T&url=http%3A%2F%2Fwww.empowher.com%2Fnews%2Fherarticle%2F2010%2F01%2F26%2Fvaccine-may-mop-leukemia-cells-gleevec-leaves-behind&usg=AFQjCNFF-L8PgMz7QTVWYDBVXC0sKYAOLg
Excerpt
...day revealed a genetic abnormality called the Philadelphia chromosome that is the signature of chronic myelogenous leukemia, or CML, a blood cell cancer that in the last decade has been transformed from ultimately fatal to nearly always treatable, usually...
Source Info
Berkshire Eagle Online
Related Topics
http://www.berkshireeagle.com/health/ci_14262987?source=rss
Court OKs pricing of Novartis' anti-leukemia drugTrading Markets (press release)Gleevec is used to treat patients with chronic myelogenous leukemia (CML), a form of blood cancer in which the body produces too many abnormal white blood ...and more »
http://news.google.com/news/url?fd=R&sa=T&url=http%3A%2F%2Fwww.tradingmarkets.com%2Fnews%2Fstock-alert%2Fnvs_court-oks-pricing-of-novartis-anti-leukemia-drug-723437.html&usg=AFQjCNHBrulGHMkgeEZIUap1qbnR1IR9xA
Living With a Formerly Fatal Blood CancerNew York TimesA bone marrow test the next day revealed a genetic abnormality called the Philadelphia chromosome that is the signature of chronic myelogenous leukemia, ...and more »
http://news.google.com/news/url?fd=R&sa=T&url=http%3A%2F%2Fwww.nytimes.com%2F2010%2F01%2F19%2Fhealth%2F19brod.html&usg=AFQjCNEDuCVREDC0CMw8elfbOsbs4YrfLQ
Deletions of Immunoglobulin heavy chain and T cell receptor gene regions are ...7thSpace Interactive (press release)Chronic myelogenous leukemia (CML) results from the neoplastic transformation of a haematopoietic stem cell. The hallmark genetic abnormality of CML is a ...
http://news.google.com/news/url?fd=R&sa=T&url=http%3A%2F%2F7thspace.com%2Fheadlines%2F331632%2Fdeletions_of_immunoglobulin_heavy_chain_and_t_cell_receptor_gene_regions_are_uniquely_associated_with_lymphoid_blast_transformation_of_chronic_myeloid_leukemia.html&usg=AFQjCNF9qlN55G_em_U1sij6Xmo1nFAa6g
Excerpt
...Bcr-Abl and Lyn-kinase inhibitor, which is currently being planned as a third-line treatment for patients with chronic myeloid leukemia (CML) or certain forms of acute myeloid leukemia (AML) that are refractory or intolerant of other approved treatments. In...
Source Info
Medical News Today
Related Topics
http://mnt.to/f/3wm6
Advances in Genetics and Treatment Protocols Lead to Significant Progress in ...Cancer Network“Omacetaxine is the first drug to show consistent activity in patients with chronic myeloid leukemia who are affected with the T315I mutation,” said lead ...
http://news.google.com/news/url?fd=R&sa=T&url=http%3A%2F%2Fwww.cancernetwork.com%2Fcme%2Farticle%2F10165%2F1510806&usg=AFQjCNHn_AXqJK9djujs2N0dd6ZrqhblUA
Study Weighs Comparative Effectiveness of Low-risk Prostate Cancer TreatmentsNCI Cancer BulletinIn an early phase clinical trial testing a therapeutic vaccine in patients with chronic myeloid leukemia (CML) who were taking the drug imatinib (Gleevec), ...and more »
http://news.google.com/news/url?fd=R&sa=T&url=http%3A%2F%2Fwww.cancer.gov%2Fncicancerbulletin%2F011210%2Fpage3&usg=AFQjCNF5o9Lm0dZGxYG2qLuLgjqSUEOCbw
checkorphan newsflash for Monday, January 11, 2010: breaking news about rare diseases, orphan diseases, orphan drugs, and neglected diseases. Today's broadcast highlights topics about: Johns Hopkins Children's Center, H1N1, Johns Hopkins, sickle cell disease, asthma, HIV, Swine flu, H1N1 treatment, tuberculosis, birth weight, Johns Hopkins Kimmel Cancer Center, leukemia, chronic myeloid leukemia, Imatinib mesylate, Gleevec, CML patients, leukemic cells, cancerous cells, Clinical Cancer Research, antigens, FACES, National Craniofacial Association, craniofacial deformities, birth defects, Ride 4 Smiles www.faces-cranio.org checkorphan.getreelhealth.com www.checkorphan.org
There's a new old drug for chronic myeloid leukemia, and it seems to work in patients who don't respond to any of the approved therapies for this disease. Dr. Jorge Cortes discusses the potential of omacetaxine mepesuccinate at the annual meeting of the American Society of Hematology.
Update Sources